Zoledronic acid (ZA) as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells (DTC) in bone marrow (BM)

被引：1
|
作者：
Lin, A. [1 ]
Park, J. [1 ]
Melisko, M. [1 ]
Goga, A. [1 ]
Moasser, M. [1 ]
Moore, D. [1 ]
Rugo, H. [1 ]
机构：
[1] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(08)70558-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [1] Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow
    Lin, A. Y.
    Park, J. W.
    Scott, J.
    Melisko, M.
    Goga, A.
    Moasser, M. M.
    Moore, D. H.
    Rugo, H. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results.
    Greenberg, S.
    Park, J. W.
    Melisko, M. E.
    Goga, A.
    Moasser, M. M.
    Anderson, M.
    Scott, J. H.
    Petrillo, L. A.
    Moore, D. H.
    Rugo, H. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow.
    Lin A
    Park J
    Melisko M
    Goga A
    Moasser M
    Moore D
    Brissaud C
    Rugo H
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S40 - S40
  • [4] Long term follow up (LTFU) of adjuvant zoledronic acid (ZOL) in high risk early stage breast cancer (ESBC) defined by bone marrow (BM) disseminated tumor cells (DTC).
    Vidula, Neelima
    Hwang, Jimmy
    Greenberg, Sally
    Melisko, Michelle E.
    Goga, Andrei
    Moasser, Mark
    Cudos, Ariadna Gasol
    Angelidakis, Austin Nicholas
    DeLuca, Amy
    Petrillo, Laura A.
    Magbanua, Mark Jesus Mendoza
    Park, John
    Rugo, Hope S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Sunitinib as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow
    Li, J.
    Melisko, M. E.
    Munster, P. N.
    Pelayo, M.
    Moasser, M. M.
    Chien, A. J.
    Scott, J.
    Esserman, L.
    Park, J. W.
    Rugo, H. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] ADJUVANT ZOLEDRONIC ACID (ZOL) THERAPY DECREASES THE PREVALENCE OF DISSEMINATED TUMOR CELLS (DTCS) IN BONE MARROW (BM) OF PATIENTS WITH EARLY-STAGE BREAST CANCER (EBC): 2-YEAR RESULTS
    Lin, A. Y.
    Park, J. W.
    Scott, J.
    Melisko, M.
    Goga, A.
    Moasser, M.
    Moore, D.
    Rugo, H.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 86 - 86
  • [7] Effect of zoledronate on persisting disseminated tumor cells (DTC) in the bone marrow (BM) of breast cancer patients
    Rack, B.
    Janni, W.
    Thieleke, W.
    Schindlbeck, C.
    Strobl, B.
    Kentenich, C.
    Blankenstein, T.
    Rjosk, D.
    Sommer, H.
    Friese, K.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 107 - 107
  • [8] Efficacy of zoledronic acid for the reduction of bone marrow tumor cells in breast cancer patients receiving adjuvant therapy
    Solomayer, EF
    Fehm, T
    Gebauer, G
    Janni, W
    Lück, HJ
    Wallwiener, D
    [J]. BONE, 2006, 38 (03) : S84 - S84
  • [9] Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients
    Solomayer, E.
    Gebauer, G.
    Hirnle, P.
    Janni, W.
    Lueck, H. J.
    Becker, S.
    Huober, J.
    Kraemer, B.
    Wackwitz, B.
    Fehm, T.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 171S - 171S
  • [10] Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients
    Fehm, T.
    Solomayer, E.
    Gebauer, G.
    Janni, W.
    Lueck, H-J
    Becker, S.
    Huober, J.
    Wackwitz, B.
    Hirnle, P.
    [J]. ONKOLOGIE, 2010, 33 : 28 - 28
12345